Enara Bio, an Oxford-based biotech, receives significant backing from Pfizer and the Francis Crick Institute.
- The company announces a successful $32.5 million Series B funding round, marking a major milestone.
- Enara Bio’s antigen discovery platform shows promise in cancer research, gaining investor interest.
- Rana Al-Hallaq from Pfizer Ventures emphasises the potential of ‘Dark Antigens’ in immunotherapy.
- Enara Bio’s ongoing collaborations highlight its industry impact, including a notable partnership with Boehringer Ingelheim.
Enara Bio, a pioneering biotech company based in Oxford, has garnered substantial support from industry giants Pfizer and the Francis Crick Institute. This backing is reflected in the successful completion of a $32.5 million Series B funding round, an indication of confidence in the firm’s innovative approach to cancer treatment. Founded in 2016, Enara Bio claims a significant breakthrough with the development of its antigen discovery platform.
With cancer continuing to be a formidable public health challenge, as evidenced by over three million estimated patients in the UK and approximately 167,000 deaths annually, the pursuit of novel therapeutic solutions remains imperative. Enara Bio’s advancement has attracted the attention of major investors, with the latest funding round being led by Pfizer’s venture capital division, alongside participation from M Ventures.
Rana Al-Hallaq, Ph.D., a partner at Pfizer Ventures, acknowledges that despite significant strides in cancer immunotherapy over recent years, only a minority of patients with solid tumours benefit substantially from existing treatments. She points out that ‘Dark Antigens’ may hold the key to unlocking the full potential of immunotherapy for a broader patient demographic, expressing satisfaction in Pfizer’s support of Enara’s cutting-edge development.
Further investment was also secured from the prestigious Francis Crick Institute and existing stakeholders like RA Capital, Samsara BioCapital, and SV Health Investors. Previously, Enara Bio raised $17.5 million during its Series A round in 2019, demonstrating steady financial growth and increasing investor confidence.
Enara Bio’s innovative EDAPT platform, notable for its capability to discover cancer antigens from ‘genomic dark matter’, is central to its research efforts. This platform is not only used internally but is also licensed to major pharmaceutical entities such as Boehringer Ingelheim, which extended its partnership with Enara Bio in 2023.
The company’s recent financial health is reflected by a substantial increase in turnover, reaching £17.4 million in 2023, and a transition to £1 million in pre-tax profits, a remarkable improvement from the previous year’s £14 million loss. Enara Bio continues to benefit from significant tax benefits, facilitated by its substantial investment of £8.6 million in research and development.
Enara Bio’s transformative work in cancer treatment research continues to garner significant financial and strategic support, highlighting its pivotal role in the biotech industry.
